[1]
|
Hindricks, G., Potpara, T., Dagres, N., et al. (2021) 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Developed with the Special Contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal, 42, 373-498. https://doi.org/10.1093/eurheartj/ehaa612
|
[2]
|
心房颤动基层诊疗指南(2019年) [J]. 中华全科医师杂志, 2020, 19(6): 465-473.
|
[3]
|
中华医学会心电生理和起搏分会, 中国医师协会心律学专业委员会, 中国房颤中心联盟心房颤动防治专家工作委员会. 心房颤动: 目前的认识和治疗建议(2021) [J]. 中华心律失常学杂志, 2022, 26(1): 15-88.
|
[4]
|
Macle, L., Cairns, J., Leblanc, K., et al. (2016) 2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology, 32, 1170-1185.
https://doi.org/10.1016/j.cjca.2016.07.591
|
[5]
|
Chang, S.H., Chou, I.J., Yeh, Y.H., et al. (2017) Association be-tween Use of Non-Vitamin K Oral Anticoagulants with and without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation. JAMA, 318, 1250-1259. https://doi.org/10.1001/jama.2017.13883
|
[6]
|
January, C.T., Wann, L.S., Calkins, H., et al. (2019) 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm, 16, e66-e93. https://doi.org/10.1016/j.hrthm.2019.01.024
|
[7]
|
Leyva, F. and Plummer, C.J. (2015) National Institute for Health and Care Excellence 2014 Guidance on Cardiac Implantable Electronic Devices: Health Economics Reloaded. Europace, 17, 339-342.
https://doi.org/10.1093/europace/euu384
|
[8]
|
Chong, D.T. andreotti, F., Verhamme, P., et al. (2021) Direct Oral Anticoagulants in Asian Patients with Atrial Fibrillation: Consensus Recommendations by the Asian Pacific Society of Cardiology on Strategies for Thrombotic and Bleeding Risk Management. European Cardiology, 16, e23. https://doi.org/10.15420/ecr.2020.43
|
[9]
|
Proietti, M., Rivera-Caravaca, J.M., Esteve-Pastor, M.A., et al. (2018) Predicting Bleeding Events in Anticoagulated Patients with Atrial Fibrillation: A Comparison between the HAS-BLED and GARFIELD-AF Bleeding Scores. Journal of the American Heart Association, 7, e009766. https://doi.org/10.1161/JAHA.118.009766
|
[10]
|
Wastesson, J.W., Morin, L., Tan, E.C.K., et al. (2018) An Update on the Clinical Consequences of Polypharmacy in Older Adults: A Narrative Review. Expert Opinion on Drug Safety, 17, 1185-1196.
https://doi.org/10.1080/14740338.2018.1546841
|
[11]
|
Trevisan, M., Hjemdahl, P., Clase, C.M., et al. (2022) Cardiorenal Outcomes among Patients with Atrial Fibrillation Treated with Oral Anticoagulants. American Journal of Kidney Diseases. https://doi.org/10.1053/j.ajkd.2022.07.017
|
[12]
|
Durand, M., Schnitzer, M.E., Pang, M., et al. (2020) Comparative Effectiveness and Safety of Direct Oral Anticoagulants versus Vitamin K Antagonists in Nonvalvular Atrial Fibrillation: A Canadian Multicentre Observational Cohort Study. CMAJ Open, 8, E877-E886. https://doi.org/10.9778/cmajo.20200055
|
[13]
|
Carrier, M., Khorana, A.A., Zwicker, J., et al. (2013) Management of Challenging Cases of Patients with Cancer-Associated Thrombosis Including Recurrent Thrombosis and Bleeding: Guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 11, 1760-1765. https://doi.org/10.1111/jth.12338
|
[14]
|
James, P.D., Connell, N.T., Ameer, B., et al. (2021) ASH ISTH NHF WFH 2021 Guidelines on the Diagnosis of Von Willebrand Disease. Blood Advances, 5, 280-300. https://doi.org/10.1182/bloodadvances.2020003265
|
[15]
|
Okumura, K., Akao, M., Yoshida, T., et al. (2020) Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation. The New England Journal of Medicine, 383, 1735-1745. https://doi.org/10.1056/NEJMoa2012883
|
[16]
|
Potter, A.S., Patel, A., Khawaja, M., et al. (2022) Outcomes by Class of Anticoagulant Use for Nonvalvular Atrial Fibrillation in Patients with Active Cancer. JACC: CardioOncology, 4, 341-350.
https://doi.org/10.1016/j.jaccao.2022.07.004
|
[17]
|
Beier, L., Lu, S., Franca, L.R., et al. (2022) Evolution of An-tithrombotic Therapy for Patients with Atrial Fibrillation: The Prospective Global GLORIA-AF Registry Program. PLOS ONE, 17, e0274237.
https://doi.org/10.1371/journal.pone.0274237
|
[18]
|
Lip, G.Y.H., Keshishian, A., Li, X., et al. (2018) Effectiveness and Safety of Oral Anticoagulants among Nonvalvular Atrial Fibrillation Patients. Stroke, 49, 2933-2944. https://doi.org/10.1161/STROKEAHA.118.020232
|
[19]
|
Ruff, C.T., Giugliano, R.P., Braunwald, E., et al. (2014) Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Meta-Analysis of Randomised Trials. The Lancet, 383, 955-962. https://doi.org/10.1016/S0140-6736(13)62343-0
|
[20]
|
Graham, D.J., Baro, E., Zhang, R., et al. (2019) Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation. The American Journal of Medicine, 132, 596-604e11. https://doi.org/10.1016/j.amjmed.2018.12.023
|
[21]
|
Pan, K.L., Singer, D.E., Ovbiagele, B., et al. (2017) Effects of Non-Vitamin K Antagonist Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis. Journal of the American Heart Association, 6, e005835. https://doi.org/10.1161/JAHA.117.005835
|
[22]
|
Sun, B., Chen, R.R., Gao, C., et al. (2022) Comparison of Out-comes between Novel Oral Anticoagulants and Warfarin Monotherapy in Patients with Left Atrial Appendage Closure: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 9, Article ID: 1023941. https://doi.org/10.3389/fcvm.2022.1023941
|
[23]
|
Mikami, T., Hirabayashi, K., Okawa, K., et al. (2022) Laboratory Test Predictors for Major Bleeding in Elderly (>/= 80 Years) Patients with Nonvalvular Atrial Fibrillation Treated with Edoxaban 15 mg: Sub-Analysis of the ELDERCARE-AF Trial. Journal of the American Heart Association, 11, e024970.
https://doi.org/10.1161/JAHA.122.024970
|
[24]
|
Bielecka, B., Gorczyca-Glowacka, I. and Wozakowska-Kaplon, B. (2022) Nine-Year Trends in Prevention of Thromboembolic Complications in Elderly Patients with Atrial Fibrillation Treated with NOACs. International Journal of Environmental Research and Public Health, 19, Article No. 11938. https://doi.org/10.3390/ijerph191911938
|